The Journal of the Korean Society for Therapeutic Radiology and Oncology  2009;27(3):120-125

doi:10.3857/jkstro.2009.27.3.120

The Preliminary Results of Intensity-Modulated Radiotherapy for Tonsillar Cancer.

Geumju PARK 1 ; Sang Wook LEE ; Eun Kyung CHOI ; Jong Hoon KIM ; Si Yeol SONG ; Sang Min YOUN ; Sung Ho PARK ; Dong Wook PARK ; Seung Do AHN

Affiliations

+expand

Keywords

Tonsillar cancer; Intensity-modulated radiotherapy; Radiotherapy

Country

Republic of Korea

Language

Korean

Abstract

PURPOSE: We wanted to present the preliminary results of intensity-modulated radiotherapy (IMRT) for the treatment of tonsillar cancer. MATERIALS AND METHODS: We retrospectively analyzed 12 patients who underwent IMRT for tonsillar cancer at Asan Medical Center between November 2002 and February 2007. Seven patients (58%) received definitive treatment, and five (42%) were treated in the postoperative setting. Among the definitively treated patients, 6 patients received cisplatin-based chemotherapy regimens. Simultaneous modulated accelerated radiation therapy (SMART) was used in nine patients. The prescribed dose was 72 Gy at 2.4 Gy/fraction for the definitively treated cases and 61.6 Gy at 2.2 Gy/fraction for the postoperative cases. The median follow-up period was 34 months. RESULTS: All twelve patients completed treatment without interruption, and eleven showed a complete response. One patient had persistent loco-regional disease after treatment. The three-year estimates of loco-regional control, disease-free survival and overall survival were 91.7%, 91.7%, and 100%. The worst acute mucositis was Grade 1 in four patients, Grade 2 in five patients, Grade 3 in two patients and Grade 4 in one patient. Grade 3 xerostomia was observed in six patients. CONCLUSION: Intensity-modulated radiotherapy was shown to be a safe and effective treatment modality for tonsillar cancer. Further studies with a larger number of patients and a longer follow-up period are needed to evaluate the ultimate tumor control and late toxicity of IMRT for treating tonsillar cancer.